Overview
Pavel Abramov practices practicing medicine in Nikolayev, Russian Federation.
His clinical expertise encompasses Von Hippel-Lindau (VHL) Syndrome and Renal Cell Carcinoma (RCC).
He is actively involved in clinical research, co-authoring 69 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Pavel A. Abramov
Is Pavel A. Abramov a top-rated expert for Von Hippel-Lindau (VHL) Syndrome?
MediFind is an objective health platform that identifies experts based on real-world data. Pavel A. Abramov is classified as an Experienced expert for Von Hippel-Lindau (VHL) Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Pavel A. Abramov participate in research or clinical trials?
Yes. Pavel A. Abramov has published 69 articles and abstracts on conditions like Von Hippel-Lindau (VHL) Syndrome. You can view a list of Pavel A. Abramov's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Renal Cell Carcinoma (RCC)Mr. Abramov isExperienced. Learn about Renal Cell Carcinoma (RCC).
- Von Hippel-Lindau (VHL) SyndromeMr. Abramov isExperienced. Learn about Von Hippel-Lindau (VHL) Syndrome.